EXEL News and Press, Exelixis Inc. From 01/08/23

– Cabozantinib franchise achieves approximately $1.4 billion in preliminary U.S. net product revenues for full year 2022, including approximately $375 million for fourth quarter 2022 – – Full year 2023 net product revenues guidance of $1,575 millio...

Exelixis, Inc. (Nasdaq: EXEL) today announced that Michael M. Morrissey, Ph.D., the company’s President and Chief Executive Officer, will provide a corporate overview at the 41 st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 8:15pm ET / 5:15pm PT. To acces...

Exelixis (NASDAQ: EXEL) is not the most popular drugmaker around, but there are several noteworthy things about this mid-cap stock. First, it is laser focused on just one area, oncology, which is the largest and one of the fastest-growing therapeutic areas in the industry. Second, Exeli...

Exelixis ( NASDAQ: EXEL ) said it started a phase 3 trial of zanzalintinib to treat a type of kidney cancer. The study, dubbed STELLAR-304, is evaluating zanzalintinib (XL092) in combination with Bristol-Myers Squibb's Opdivo (nivolumab), versus Pfizer's&#...

– STELLAR-304 is the second phase 3 pivotal trial evaluating zanzalintinib, a next-generation tyrosine kinase inhibitor in development for multiple advanced tumor types – Exelixis, Inc. (Nasdaq: EXEL) today announced the initiation of STELLAR-304, a phase 3 pivotal t...

A mistake that many investors are making today is assuming that things will only get worse, and that now is a time to sell stocks. But just as stocks weren't destined to continue soaring last year as meme investments were rising to ridiculous valuations, the sky isn't falling right now either. ...

Oncology-focused biotech Exelixis, Inc. ( NASDAQ: EXEL ) has announced that its tyrosine kinase inhibitor cabozantinib in combination with Roche’s ( OTCQX:RHHBY ) ( OTCQX:RHHBF ) anti-PD-1/PD-L1 therapy atezolizumab did not meet the primary goal of overall survival in a Pha...

Exelixis, Inc. (Nasdaq: EXEL) today announced that the CONTACT-01 study did not meet its primary endpoint of overall survival at the final analysis. CONTACT-01 is a phase 3 trial evaluating cabozantinib (CABOMETYX ® ) in combination with atezolizumab (TECENTRIQ ® ) versus doce...

– In the QUARTZ-101 trial, XL102 — a novel cyclin-dependent kinase 7 inhibitor — was well tolerated at evaluated dose levels – Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 ...

High conviction. That's what you want to have with the stocks you buy. Such stocks are ones that you can be enthusiastic about -- and buy heavily. We asked three Motley Fool contributors to identify stocks for which they have high convictions about buying right now. Here's why they think that...